When you think of biotech hubs, the first image that comes to mind may be the sleek waterfront offices of Boston Seaport or ...

Bicycle Therapeutics is reducing its headcount by around 25% to extend its cash runway into 2028. | Bicycle Therapeutics is ...

Genomics is stepping up to buy Scale Biosciences and its single-cell profiling solutions, with plans to implement them within ...

Longevity company Altos Labs has secured a new clinical leader from the eye of the storm. Former Tornado Therapeutics ...

An impressive array of Big Pharma backers have lined up to ensure Strand Therapeutics has the funding needed to take its mRNA ...

After emerging from stealth earlier this year, Apreo Health has raised $130 million to breathe new life into the development ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...

In its own statement, Edwards said it disagrees with the FTC’s belief that the acquisition will limit access to a new therapy ...

When Tiba Biotech was included in the cancelation of $500 million worth grants funding mRNA vaccine development, the company ...

Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead is cleaning up its R&D pipeline. | After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, ...